To provide that the approved application under the Federal Food, Drug, and Cosmetic Act for the drug mifepristone for the purpose of the termination of intrauterine pregnancy is deemed to have been withdrawn, to establish a Federal tort for harm to women caused by chemical abortion drugs, and for other purposes.
Summary
HR 7902 (Safeguarding Women from Chemical Abortion Act) would withdraw FDA approval for mifepristone for pregnancy termination and create a federal tort for harm from chemical abortion drugs. The bill was introduced March 12, 2026, referred to two committees, and is in early legislative stages with only 6 cosponsors. Revenue exposure for $PFE and $TEVA is immaterial to their overall financials — less than 0.1% of revenue for each. The bill has effectively no near-term market impact.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR 7902 is early-stage legislation with very low near-term passage probability (6 cosponsors, no committee action)
- 2.Revenue exposure to $PFE and $TEVA is immaterial — less than 0.1% of annual revenue for either company
- 3.$TEVA's 15% weekly gain and $PFE's 5% monthly decline are driven by company-specific catalysts, not abortion legislation
- 4.No federal spending is authorized — funding_amount is $0
Market Implications
This bill has negligible market implications. $PFE at $26.71 (near 52-week low of $21.97) faces headwinds from LoE on Xeljanz, Ibrance, and Eliquis patent cliffs — not from a low-revenue product like mifepristone. $TEVA at $35.26 (near 52-week high of $37.35) is rallying on positive pipeline news and AJOVY/COPAXONE generic defense. Traders should not factor HR 7902 into positions on either stock. The only scenario that would change the market calculus is a surprise markup or hearing scheduling that signals bill progression — currently no evidence of that.
Full Analysis
HR 7902 was introduced in the House on March 12, 2026 by Representative Harshbarger (R-TN) with 6 cosponsors. It has been referred to the Committee on Energy and Commerce and the Committee on the Judiciary. A companion bill (S4066) has been introduced in the Senate and referred to HELP Committee. The bill is in very early legislative stages — neither committee has held hearings or marked up the bill. Passage probability in the 119th Congress is low given the limited cosponsor support, divided government context, and the fact that similar bills have not advanced in prior sessions.
The bill operates through two mechanisms: (1) deeming the FDA-approved application for mifepristone for pregnancy termination withdrawn after 14 days of enactment, making introduction into interstate commerce a violation of the FD&C Act; (2) establishing a federal tort cause of action for women harmed by chemical abortion drugs. The bill does not authorize or appropriate any federal spending — funding_amount_usd is $0.
Structural winners and losers: There are no material winners from this bill. The only identified losers are $PFE and $TEVA, which manufacture branded and generic mifepristone respectively. However, the US mifepristone market for pregnancy termination (the relevant portion) is estimated at approximately $30-50M annually — a rounding error for Pfizer's $58B+ and Teva's $16B in annual revenue. Neither company has meaningful dependence on this product line.
Real market data analysis: $PFE is trading at $26.71, down -1.11% over 7 days and -4.91% over 30 days. The stock has been declining from $27.56 on April 17 to $26.70 on April 30. This decline is attributable to broader pharma sector trends (patent cliff concerns, pipeline readouts) — not to this bill. $TEVA is trading at $35.26, up +15.08% over 7 days and +17.07% over 30 days, driven by positive late-stage trial data for olanzapine LAI and generic launch timelines — not related to mifepristone legislation.
Remaining legislative path: The bill must pass through two House committees (Energy & Commerce; Judiciary) before a floor vote, then clear the Senate (where companion S4066 faces similar hurdles), then be signed by the President. No hearings are scheduled. Given the early stage and limited momentum, realistic timeline for any movement would be late 2026 at the earliest, if at all.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Withdrawal of FDA approval for mifepristone for pregnancy termination (section 2 of bill) - directly impacts Pfizer's branded Mifeprex product
Who must act
Pfizer Inc. (manufacturer of branded mifepristone/Mifeprex)
What happens
If enacted, Pfizer would be prohibited from commercializing mifepristone for the labeled indication of pregnancy termination; remaining approved uses (Cushing's syndrome) unaffected; product effectively removed from the US abortion market
Stock impact
Mifepristone for pregnancy termination contributes an immaterial fraction of Pfizer's ~$58B annual revenue (less than 0.1%); Pfizer's primary businesses are vaccines (Comirnaty, Prevnar), oncology (Ibrance, Xtandi, Eliquis), and inflammation; no material financial impact
What the bill does
Withdrawal of FDA approval for generic mifepristone products referencing branded mifeprex (section 2(1) of bill)
Who must act
Teva Pharmaceutical Industries Ltd. (generic manufacturer of mifepristone)
What happens
Teva's authorized generic mifepristone would be withdrawn from the US market for pregnancy termination indication; no impact on Teva's non-abortion product lines (CNS, respiratory, oncology generics)
Stock impact
Teva's mifepristone generic is a low-revenue product; Teva's 2025 total revenue is approximately $16B; the entire US mifepristone market (branded + generic) is estimated at less than $50M annually; impact on Teva is immaterial
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Skinny Labels, Big Savings Act
ADVANCED TECHNOLOGY INTERNATIONAL: $304M Department of Health and Human Services Contract
American Innovation and R&D Competitiveness Act of 2025
To amend title XVIII of the Social Security Act to ensure equitable payment for, and preserve Medicare beneficiary access to, cancer treatments under the Medicare hospital outpatient prospective payment system.
TRIWEST HEALTHCARE ALLIANCE CORP: $929M Department of Veterans Affairs Contract
Growing and Preserving Innovation in America Act of 2025
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Price Gouging Prevention Act of 2025
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.